Atorvastatin prevents Aβ oligomer-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting Tau cleavage

Acta Pharmacol Sin. 2015 May;36(5):553-64. doi: 10.1038/aps.2014.161. Epub 2015 Apr 20.

Abstract

Aim: The proteolytic cleavage of Tau is involved in Aβ-induced neuronal dysfunction and cell death. In this study, we investigated whether atorvastatin could prevent Tau cleavage and hence prevent Aβ1-42 oligomer (AβO)-induced neurotoxicity in cultured cortical neurons.

Methods: Cultured rat hippocampal neurons were incubated in the presence of AβOs (1.25 μmol/L) with or without atorvastatin pretreatment. ATP content and LDH in the culture medium were measured to assess the neuronal viability. Caspase-3/7 and calpain protease activities were detected. The levels of phospho-Akt, phospho-Erk1/2, phospho-GSK3β, p35 and Tau proteins were measured using Western blotting.

Results: Treatment of the neurons with AβO significantly decreased the neuronal viability, induced rapid activation of calpain and caspase-3/7 proteases, accompanied by Tau degradation and relatively stable fragments generated in the neurons. AβO also suppressed Akt and Erk1/2 kinase activity, while increased GSK3β and Cdk5 activity in the neurons. Pretreatment with atorvastatin (0.5, 1, 2.5 μmol/L) dose-dependently inhibited AβO-induced activation of calpain and caspase-3/7 proteases, and effectively diminished the generation of Tau fragments, attenuated synaptic damage and increased neuronal survival. Atorvastatin pretreatment also prevented AβO-induced decreases in Akt and Erk1/2 kinase activity and the increases in GSK3β and Cdk5 kinase activity.

Conclusion: Atorvastatin prevents AβO-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting calpain- and caspase-mediated Tau cleavage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Peptides / toxicity*
  • Animals
  • Atorvastatin / pharmacology*
  • Calpain / antagonists & inhibitors
  • Calpain / metabolism
  • Caspase 3 / metabolism
  • Caspase 7 / metabolism
  • Caspase Inhibitors / pharmacology
  • Cell Survival / drug effects
  • Cells, Cultured
  • Cyclin-Dependent Kinase 5 / metabolism
  • Cytoprotection
  • Dose-Response Relationship, Drug
  • Enzyme Activation
  • Glycogen Synthase Kinase 3 / metabolism
  • Glycogen Synthase Kinase 3 beta
  • Hippocampus / drug effects*
  • Hippocampus / embryology
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Neurons / drug effects*
  • Neurons / metabolism
  • Neurons / pathology
  • Neuroprotective Agents / pharmacology*
  • Peptide Fragments / toxicity*
  • Phosphorylation
  • Protease Inhibitors / pharmacology
  • Proteolysis
  • Rats, Sprague-Dawley
  • Signal Transduction / drug effects
  • Time Factors
  • tau Proteins / metabolism*

Substances

  • Amyloid beta-Peptides
  • Caspase Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Mapt protein, rat
  • Neuroprotective Agents
  • Peptide Fragments
  • Protease Inhibitors
  • amyloid beta-protein (1-42)
  • tau Proteins
  • Atorvastatin
  • Cyclin-Dependent Kinase 5
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, rat
  • Cdk5 protein, rat
  • Glycogen Synthase Kinase 3
  • Calpain
  • Casp3 protein, rat
  • Caspase 3
  • Caspase 7